← Back to patent-cliff list
AZD-2287
Tier C — Watch / tradeAZD-2287
AstraZeneca
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
In vivo diagnostic
Type
Targets：Updating
Indications (approved)：Prostate cancer, Castration-resistant prostate cancer
Regional status
US
Phase II
2026-06-03
EU
Phase II
2026-06-03
China
Phase I
2026-08-26
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AZD-2287?
Approved indications include: Prostate cancer, Castration-resistant prostate cancer.
When does the AZD-2287 patent expire?
No public expiry year is available for AZD-2287 yet; this page updates once verified.
How do I get a quote for AZD-2287 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29